---
id: toxoplasmosis_096
category: organisms
tags: [toxoplasmosis, Toxoplasma-gondii, HIV-OI, congenital-infection, TORCH]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Toxoplasmosis

**Q:** What are the clinical syndromes, diagnosis, and treatment of toxoplasmosis in immunocompromised vs immunocompetent hosts?

**A:**

## OVERVIEW

**Organism:** *Toxoplasma gondii* (intracellular protozoan parasite)

**Transmission:**
- **Cat feces** (oocysts) - definitive host
- **Undercooked meat** (tissue cysts - pork, lamb, venison)
- **Congenital** (transplacental)
- **Transplant** (donor organ - heart most common)

**Epidemiology:**
- **~11% US seroprevalence** (30-50% worldwide)
- **Most infections asymptomatic** (immunocompetent)

---

## CLINICAL SYNDROMES

---

### **1. CNS Toxoplasmosis in HIV (Most Common)**

**Epidemiology:**
- **CD4 <100 cells/μL** (85% have CD4 <50)
- **#1 cause of focal brain lesions** in AIDS

**Pathophysiology:**
- **Reactivation** of latent cysts (chronic infection)

**Clinical Features:**
- **Focal neurologic deficits** (hemiparesis, aphasia) - 60-80%
- **Headache** (50%)
- **Seizures** (30%)
- **Altered mental status** (50%)
- **Fever** (50%)

**Imaging (MRI Brain with Contrast - GOLD STANDARD):**
- **Multiple ring-enhancing lesions** (80%)
- **Basal ganglia, corticomedullary junction** (predilection)
- **Mass effect, edema**
- **T2 "eccentric target sign"** (nodule within ring)

**Key Point:** **Multiple ring-enhancing lesions + CD4 <100 = toxoplasmosis** until proven otherwise

---

**Differential Diagnosis:**

| **Disease** | **MRI Features** | **Other Clues** |
|-------------|------------------|-----------------|
| **Toxoplasmosis** | Multiple ring-enhancing lesions (basal ganglia) | CD4 <100, Toxo IgG+ (95%) |
| **Primary CNS Lymphoma (PCNSL)** | Single periventricular lesion, **crosses midline** | EBV PCR+ in CSF, Toxo IgG- |
| **Progressive Multifocal Leukoencephalopathy (PML)** | **NO enhancement**, subcortical white matter | JC virus PCR+ in CSF |

**Key Point:** **Toxo vs PCNSL:** Multiple lesions = toxo, single lesion crossing midline = PCNSL

---

### **2. Congenital Toxoplasmosis (TORCH)**

**Risk:**
- **Primary maternal infection** during pregnancy (NOT reactivation)
- **Risk of transmission:** 1st trimester (10-15%) < 3rd trimester (60-80%)
- **Severity:** 1st trimester (most severe) > 3rd trimester (often asymptomatic)

**Classic Triad (Late Manifestations):**
- **Retinochoroiditis** (chorioretinitis)
- **Hydrocephalus**
- **Intracranial calcifications** (diffuse, scattered - **vs CMV = periventricular**)

**Acute Neonatal Manifestations:**
- **Hepatosplenomegaly**
- **Jaundice**
- **Thrombocytopenia**
- **Rash** (blueberry muffin)
- **Microcephaly** or **Hydrocephalus**
- **Seizures**

**Key Point:** **Diffuse intracranial calcifications = Toxo** (vs **periventricular = CMV**)

---

### **3. Ocular Toxoplasmosis (Retinochoroiditis)**

**Epidemiology:**
- **Most common cause of infectious posterior uveitis**
- Can be congenital (reactivation later in life) OR acquired

**Clinical Features:**
- **Blurred vision, floaters, photophobia**
- **Focal necrotizing retinitis** with **overlying vitritis** ("headlight in fog")
- **"Satellite lesions"** near old scars (reactivation)

**Treatment (Immunocompetent):**
- **Observation** if peripheral lesion (no vision threat)
- **Treatment if:** Vision-threatening (macula, optic nerve) OR severe vitritis
  - **Pyrimethamine** 100 mg PO loading → 25-50 mg daily
  - **PLUS Sulfadiazine** 1 g PO QID
  - **PLUS Leucovorin** 10-25 mg PO daily (prevent bone marrow suppression)
  - **PLUS Prednisone** 1 mg/kg PO daily (taper after 1-2 weeks)
  - **Duration:** 4-6 weeks

**Key Point:** **Corticosteroids ONLY if active treatment** (avoid steroids alone)

---

### **4. Toxoplasmosis in Immunocompetent Hosts**

**Clinical Features:**
- **~90% asymptomatic**
- **Lymphadenopathy** (cervical) - "toxo mono" (mimics infectious mononucleosis)
- **Fever, fatigue, myalgias**
- **Self-limited** (weeks to months)

**Treatment:**
- **Usually NOT needed** (self-limited)
- **Consider treatment if:** Severe symptoms, organ involvement, pregnant

---

## DIAGNOSIS

### **Serology:**

**IgG:**
- **Positive:** Indicates past or chronic infection (most common)
- **Negative:** No prior exposure (at risk for primary infection)

**IgM:**
- **Positive:** Suggests recent infection (can persist months to years)
- **IgG+ and IgM+:** Recent infection OR false positive IgM

**Key Point:** **IgG+ alone = chronic/latent infection** (most common in HIV patients with CNS toxo)

---

### **CNS Toxoplasmosis Diagnosis:**

**Presumptive Diagnosis (If ALL Present):**
- **CD4 <100**
- **Toxoplasma IgG positive** (95% of CNS toxo)
- **Multiple ring-enhancing brain lesions** (MRI)

**Treatment Response:**
- **Clinical improvement** within 7-14 days
- **Radiologic improvement** within 2-3 weeks

**If No Response:**
- **Brain biopsy** (rule out PCNSL, other)

---

### **PCR:**
- **CSF PCR** (low sensitivity 30-50%, high specificity 95%)
- **Amniotic fluid PCR** (congenital toxo - sensitivity 70-90%)

---

## TREATMENT

---

### **CNS Toxoplasmosis in HIV (First-Line):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Pyrimethamine** | **200 mg PO loading** → 50 mg PO daily (<60 kg) OR 75 mg daily (>60 kg) | **Acute: ≥6 weeks**<br>**THEN Chronic suppression** (lifelong unless immune reconstitution) |
| **PLUS Sulfadiazine** | **1 g PO QID** | Same |
| **PLUS Leucovorin** | **10-25 mg PO daily** (prevent bone marrow suppression from pyrimethamine) | Same |

**Transition to Suppressive Therapy:**
- After ≥6 weeks acute therapy + clinical/radiologic improvement

**Chronic Suppression (Secondary Prophylaxis):**
- **Same regimen, reduced dose:**
  - **Pyrimethamine** 25-50 mg PO daily
  - **PLUS Sulfadiazine** 500-1000 mg PO QID
  - **PLUS Leucovorin** 10-25 mg PO daily

**Discontinue Suppression:**
- If **CD4 >200 for ≥6 months** on ART AND asymptomatic AND no active lesions

---

### **Alternative Regimens (If Sulfa Allergy):**

| **Agent** | **Dosing** |
|-----------|------------|
| **Pyrimethamine** + **Leucovorin** | (same as above) |
| **PLUS Clindamycin** | **600 mg IV/PO q6h** (preferred alternative) |

**OR**

| **Agent** | **Dosing** |
|-----------|------------|
| **Trimethoprim-sulfamethoxazole (TMP-SMX)** | **5 mg/kg TMP IV q6h** (alternative if pyrimethamine unavailable) |

---

### **Adjunctive Therapy:**

**Corticosteroids:**
- **Dexamethasone** 4 mg PO/IV q6h
- **ONLY if:** Significant mass effect/edema with focal neurologic deficits
- **Taper ASAP** (risk of immunosuppression)

**Anticonvulsants:**
- **ONLY if seizures** (do NOT give prophylactically)

**Antiretroviral Therapy (ART):**
- **Start ART** within 2 weeks of toxo diagnosis (if not already on ART)

---

### **Congenital Toxoplasmosis Treatment:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Pyrimethamine** | **Loading:** 2 mg/kg PO daily x 2 days<br>**THEN:** 1 mg/kg PO daily | **12 months** |
| **PLUS Sulfadiazine** | **50 mg/kg PO BID** | 12 months |
| **PLUS Leucovorin** | **10 mg 3x/week** | 12 months |

**Corticosteroids:**
- If **chorioretinitis** OR **elevated CSF protein**
- **Prednisone** 1 mg/kg/day (taper)

---

### **Primary Prophylaxis (HIV Patients):**

**Indication:**
- **CD4 <100** AND **Toxoplasma IgG positive**

**Regimen:**
- **Trimethoprim-sulfamethoxazole (TMP-SMX)** 1 DS tablet PO daily (preferred)
- **Alternative:** TMP-SMX 1 SS tablet PO daily OR dapsone 50 mg PO daily + pyrimethamine 50 mg weekly + leucovorin 25 mg weekly

**Discontinue:**
- If **CD4 >200 for ≥3 months** on ART

**Key Point:** **TMP-SMX prophylaxis = also prevents PCP, toxo, bacterial infections**

---

## PREGNANCY SCREENING & TREATMENT

**Screening:**
- **Toxoplasma IgG** (ideally preconception or early pregnancy)
- If **IgG negative:** Counsel on avoidance (undercooked meat, cat litter)

**If Acute Infection Suspected (IgM+):**
- **Confirm with reference lab** (IgG avidity testing)
- **Amniocentesis + PCR** (after 18 weeks gestation)

**Treatment (Maternal):**

| **Trimester** | **Treatment** |
|---------------|---------------|
| **<18 weeks** | **Spiramycin** 1 g PO TID (reduces transmission, does NOT cross placenta) |
| **≥18 weeks** OR **fetal infection confirmed** | **Pyrimethamine** 50 mg PO daily + **Sulfadiazine** 1 g PO QID + **Leucovorin** 10-25 mg daily |

**Key Point:** **Spiramycin for maternal infection** (prevents transmission), **Pyrimethamine for fetal infection**

---

## PROGNOSIS

**HIV Patients:**
- **Good response** to treatment (70-90% improve)
- **Relapse common** if secondary prophylaxis not given

**Congenital Toxoplasmosis:**
- **Most asymptomatic at birth** (70-90%) → Develop late sequelae (retinochoroiditis, cognitive delays)
- **Severe disease:** 10-20% (hydrocephalus, seizures, intellectual disability)

---

**Mnemonic: "Toxo in AIDS = Multiple Rings at CD4 <100"**
- **T**oxoplasmosis
- **M**ultiple **R**ing-enhancing lesions (MRI)
- **C**D4 <100
- **B**asal ganglia, corticomedullary junction

**Mnemonic: "Toxo Triad = R-H-C (Retina, Hydrocephalus, Calcifications)"**
- **R**etinochoroiditis
- **H**ydrocephalus
- **C**alcifications (diffuse, scattered)

**Mnemonic: "Pyrimethamine Needs Leucovorin (Prevent Pancytopenia)"**
- **P**yrimethamine
- **L**eucovorin (folinic acid)
- Prevents bone marrow suppression (megaloblastic anemia, leukopenia, thrombocytopenia)

**Clinical Pearls:**
- **CNS toxo = #1 focal brain lesion in AIDS** (CD4 <100)
- **Multiple ring-enhancing lesions** = toxo until proven otherwise
- **Toxo IgG+ in 95%** of CNS toxo (reactivation of latent infection)
- **Empiric treatment trial** = 10-14 days (if no response → brain biopsy)
- **Pyrimethamine + sulfadiazine + leucovorin** = first-line for acute treatment
- **Leucovorin ESSENTIAL** (prevent bone marrow suppression from pyrimethamine)
- **Chronic suppression** until CD4 >200 x 6 months on ART
- **TMP-SMX prophylaxis** prevents PCP + toxo (CD4 <100, Toxo IgG+)
- **Congenital toxo:** Diffuse calcifications (vs CMV = periventricular)
- **Ocular toxo:** "Headlight in fog" (necrotizing retinitis + vitritis)
- **Pregnancy:** Spiramycin (prevent transmission), pyrimethamine (if fetal infection confirmed)

**Media:** None

**Sources:** [NIH/HIVMA/IDSA 2024 - Opportunistic Infections Guidelines], [CDC 2024 - Congenital toxoplasmosis case definition], [NEJM 2024 - Toxoplasmosis in HIV], [American Academy of Ophthalmology 2024 - Ocular toxoplasmosis management], [StatPearls 2024 - Toxoplasma retinochoroiditis]
